Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions
Sarcoidosis
Interventions
DRUG

Fluorodeoxyglucose

a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)

DRUG

Rubidium

used in PET scans

DIAGNOSTIC_TEST

FDG-PET/CT with Rb82 Myocardial Perfusion Imaging

A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.

Trial Locations (1)

06510

Yale New Haven Hospital, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03048097 - Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 | Biotech Hunter | Biotech Hunter